BioCorRx Inc. (BICX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Operating profit | $m | -5 | -5 | ||||||
| Net profit | $m | -4 | -6 | -4 | -4 | -5 | -3 | -3 | -4 |
| EPS reported | $ | -0.19 | -0.13 | ||||||
| Operating cashflow per share | $ | -0.12 | -0.08 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.12 | -0.08 | ||||||
| Free cash flow | $m | -2 | -2 | ||||||
| Net debt | $m | 2 | 8 | ||||||
| Book value equity | $m | -11 | -12 | ||||||
| Book value per share | $ | -0.61 | -0.42 | ||||||
| Number of shares | m | 18.49 | 29.22 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.48 | -0.44 | ||||||
| P/S LTM | x | 6.75 | 6.84 | ||||||
| P/FCF LTM | x | -2.34 | -2.28 | ||||||
| EV/EBITDA LTM | x | -2.88 | -2.23 | ||||||
| EV/Sales LTM | x | 9.25 | 16.76 | ||||||
| Earnings Yield LTM | % | -63.93% | -51.52% | ||||||
| FCF Yield | % | -42.71% | -43.77% | ||||||
| Quality | |||||||||
| ROE | % | +30.65% | +26.14% | ||||||
| ROIC | % | +1.12% | +99.54% | ||||||
| Operating margin | % | -6.06% | -6.22% | ||||||
| Gross margin | % | +86.72% | +61.07% | ||||||
| FCF/Sales | % | -288.28% | -299.44% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.08 | -0.31 | ||||||
| Net Debt/EBITDA | x | -0.78 | -2.31 | ||||||
| EBIT/Net interest | x | -5.61 | -6.54 | ||||||
| Net debt/market cap | % | +36.60% | +1.36% | ||||||
| Net debt/Equity | x | -0.16 | -0.61 | ||||||
| Gross debt/equity | x | -0.19 | -0.63 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free